One of the major findings of this paper is that DUSP13 expression is not limited to the testes or muscles but can be found in cancer cells with wild-type p53 exposed to clinically relevant substances (e.g., camptothecin), experimental drug combination (A + N), or antagonists of MDM2–p53 interaction (nutlin-3a, idasanutlin, and RG7112). This evidence concerns the gene MDM2 and cancer.